Aspirin resistance: What, why and when?

Thrombosis Research

Volumn 119, Issue 5, 2007, Pages 551-554

  Shantsila, Eduard ^a   Watson, Timothy ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; DICLOFENAC; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; THROMBIN; THROMBOXANE A2;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG MEGADOSE; EDITORIAL; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; MEDICAL RESEARCH; MEDLINE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS; UNSTABLE ANGINA PECTORIS; UPPER GASTROINTESTINAL BLEEDING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION; THROMBOXANE A2;

EID: 33847178658     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2006.08.009     Document Type: Editorial

References (46)

1. Bhatt D.L. Aspirin resistance: more than just a laboratory curiosity. J Am Coll Cardiol 43 (2004) 1127-1129
2. Hankey G.J., and Eikelboom J.W. Aspirin resistance. BMJ 328 (2004) 477-479
3. Campbell C.L., and Steinhubl S.R. Variability in response to aspirin: do we understand the clinical relevance?. J Thromb Haemost 3 (2005) 665-669
4. Bhatt D., and Topol E.J. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev 2 (2003) 15-28
5. Patrono C., Coller B., FitzGerald G.A., Hirsh J., and Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects-the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 suppl (2004) 234S-264S
6. Maclouf J., Folco G., and Patrono C. Eicosanoids and iso-eicosanoids: constitutive, inducible and transcellular biosynthesis in vascular disease. Thromb Haemost 79 (1998) 691-705
7. McNicol A., and Israels S.J. Platelets and anti-platelet therapy. J Pharmacol Sci 93 (2003) 381-396
8. Roth G.J., and Calverley D.C. Aspirin, platelets and thrombosis: theory and practice. Blood 83 (1994) 885-898
9. Patrono C., Bachmann F., Baigent C., Bode C., De Caterina R., Charbonnier B., et al. European Society of Cardiology. Expert consensus document on the use of antiplatelet agents. The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology. Eur Heart J 25 (2004) 166-181
10. Macchi L., Christiaens L., Brabant S., Sorel N., Allal J., Mauco G., et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 107 (2002) 45-49
11. Eikelboom J.W., Hankey G.J., Thom J., Claxton A., Yi Q., Gilmore G., et al. Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial. J Thromb Haemost 3 (2005) 2649-2655
12. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 1 (2003) 1710-1713
13. Rocca B., Secchiero P., Ciabattoni G., Ranelletti F.O., Catani L., Guidotti L., et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A 99 11 (2002) 7634-7639
14. Cipollone F., Ciabattoni G., Patrignani P., Pasquale M., Di Gregorio D., Bucciarelli T., et al. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 102 9 (2000) 1007-1013
15. Catella-Lawson F., Reilly M.P., Kapoor S.C., Cucchiara A.J., DeMarco S., Tournier B., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345 25 (2001) 1809-1817
16. Rich S.A. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345 23 (2001) 1709
17. Halushka M., Walker L.P., and Haushaka P.V. Genetic variation in cyclooxygenase 1. Affects on response to aspirin. Clin Pharmacol Ther 73 (2003) 122-130
18. Cambria-Kiely J.A., and Gandhi P.J. Aspirin resistance and genetic polymorphisms. J Thromb Thrombolysis 14 (2002) 51-58
19. O'Donnell C.J., Larson M.G., Feng D., Sutherland P.A., Lindpaintner K., Myers R.H., et al. Genetic and environmental contributions to platelet aggregation: the Framingham Heart Study. Circulation 103 (2001) 3051-3056
20. Hurlen M., Smith P., and Arnesen H. Effects of warfarin, aspirin and the two combined, on mortality and thromboembolic morbidity after myocardial infarction. The WARIS-II (Warfarin-Aspirin Reinfarction Study) design. Scand Cardiovasc J 34 2 (2000) 168-171
21. Quinn M., and Topol E.J. Common variations in platelet glycoproteins: pharmacogenomic implications. Pharmacogenomics 2 (2001) 341-352
22. Grundmann K., Jaschonek K., Kleine B., Dichgans J., and Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 250 (2003) 63-66
23. Grotemeyer K.H. Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Thromb Res 63 (1991) 587-593
24. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., and Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
25. Poulsen T.S., Jørgensen B., Korsholm L., Licht P.B., Haghfel T., and Mickley H. Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction. Thromb Res 119 (2007) 555-562 (this issue)
26. Carney R.M., Freedland K.E., Eisen S.A., Rich M.W., Skala J.A., and Jaffe A.S. Adherence to a prophylactic medication regimen in patients with symptomatic versus asymptomatic ischemic heart disease. Behav Med 24 (1998) 35-39
27. Friend M., Vucenik I., and Miller M. Research pointers: platelet responsiveness to aspirin in patients with hyperlipidaemia. BMJ 326 (2003) 82-83
28. Davi G., Ciabattoni G., Consoli A., Mezzetti A., Falco A., Santarone S., et al. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99 (1999) 224-229
29. 2 metabolism and results in an altered susceptibility to aspirin effects. Platelets 11 (2000) 177-182
30. Hung J., Lam J.Y., Lacoste L., and Letchacovski G. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 92 (1995) 2432-2436
31. Szczeklik A., Musial J., Undas A., Swadzba J., Gora P.F., Piwowarska W., et al. Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia. Arterioscler Thromb Vasc Biol 16 (1996) 948-954
32. Csiszar A., Stef G., Pacher P., and Ungvari Z. Oxidative stress-induced isoprostane formation may contribute to aspirin resistance in platelets. Prostaglandins Leukot Essent Fatty Acids 66 (2002) 557-558
33. Pappas J.M., Wistengard J.C., and Bull B.S. Population variability in the effect of aspirin on platelet function. Implications for clinical trials and therapy. Arch Pathol Lab Med 118 (1994) 801-804
34. RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 336 (1990) 827-830
35. Lewis Jr. H.D., Davis J.W., Archibald D.G., Steinke W.E., Smitherman T.C., Doherty III J.E., et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration cooperative study. N Engl J Med 309 (1983) 396-403
36. Theroux P., Ouimet H., McCans J., Latour J.G., Joly P., Levy G., et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 319 (1988) 1105-1111
37. McKenna R., Galante J., Bachmann F., Wallace D.L., Kaushal P.S., and Meredith P. Prevention of venous thromboembolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression. BMJ 280 (1980) 514-517
38. Harris W.H., Athanasoulis C.A., Waltman A.C., and Salzman E.W. High and low-dose aspirin prophylaxis against venous thromboembolic disease in total hip replacement. J Bone Joint Surg Am 64 (1982) 63-66
39. Farrell B., Godwin J., Richards S., and Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 54 (1991) 1044-1054
40. Antithrombotic Trialists Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 324 (2002) 71-86
41. Weber A.A., Zimmermann K.C., Meyer-Kirchrath J., and Schrör K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 353 (1999) 900
42. Lim E., Ali Z., Ali A., Routledge T., Edmonds L., Altman D.G., et al. Indirect comparison meta-analysis of aspirin therapy after coronary surgery. BMJ 327 (2003) 1309
43. ten Berg J.M., Gerritsen W.B., Haas F.J., Kelder H.C., Verheugt F.W., and Plokker H.W. High-dose aspirin in addition to daily low-dose aspirin decreases platelet activation in patients before and after percutaneous coronary intervention. Thromb Res 105 (2002) 385-390
44. Gonzalez-Conejero R., Rivera J., Corral J., Acuna C., Guerrero J.A., and Vicente V. Biological assessment of aspirin efficacy on healthy individuals. Heterogenous response or aspirin failure?. Stroke 36 (2005) 276-280
45. Anand B.S., Sanduja S.K., and Lichtenberger L.M. Effect of omeprazole on the bioavailability of aspirin: a randomized controlled study on healthy volunteers. Gastroenterology 116 (1999) A371
46. Iñarrea P., Esteva F., Cornudella R., and Lanas A. Omeprazole does not interfere with the antiplatelet effect of low-dose aspirin in man. Scand J Gastroenterol 35 (2000) 242-246